Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival
Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT...
Saved in:
Published in | Clinical cancer research Vol. 20; no. 19; pp. 5124 - 5132 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.10.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling.
Experimental design: We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells.
Results: Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth.
Conclusion: These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124–32. ©2014 AACR. |
---|---|
AbstractList | Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling.PURPOSEDeregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling.We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells.EXPERIMENTAL DESIGNWe evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells.Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth.RESULTSGene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth.These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR.CONCLUSIONThese results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR. Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling. We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells. Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth. These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR. Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling. Experimental design: We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells. Results: Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth. Conclusion: These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124–32. ©2014 AACR. |
Author | Fu, Pingfu Kluge, Amy Yang, Michael Groner, Bernd Wildey, Gary Dabir, Snehal Kresak, Adam Dowlati, Afshin |
Author_xml | – sequence: 1 givenname: Snehal surname: Dabir fullname: Dabir, Snehal – sequence: 2 givenname: Amy surname: Kluge fullname: Kluge, Amy – sequence: 3 givenname: Adam surname: Kresak fullname: Kresak, Adam – sequence: 4 givenname: Michael surname: Yang fullname: Yang, Michael – sequence: 5 givenname: Pingfu surname: Fu fullname: Fu, Pingfu – sequence: 6 givenname: Bernd surname: Groner fullname: Groner, Bernd – sequence: 7 givenname: Gary surname: Wildey fullname: Wildey, Gary – sequence: 8 givenname: Afshin surname: Dowlati fullname: Dowlati, Afshin |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25124686$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UU1vGjEQtapUCaH5Ca187GWJv3dRTytEWiRQUKFny-v1Jo4Wm9oG2n9fbwmXHHKaGc17bzTv3YIr550B4DNGE4x5dY9RWRWIUTKZzX4WmBWYUPoBjDDnZUGJ4Fe5v2BuwG2MLwhhhhG7BjeEY8JEJUbguPQnuF7UGwrnf_bBxGi9g9bBlertk1MuwZWJPj2b3vqdgosI6xi9tiqZFp5seoYLp4NRMY-bbb2lsNbJHlUadJRr4dr7ANd5NllrcwjHvOw_gY-d6qO5e61j8Othvp39KJaP3xezelloykUqNKnaCrOumSpiCFOkLTnXFOUub5Dg3JSNapiasoZzQTsmSk46pqddft0QOgZfz7r74H8fTExyZ6M2fa-c8Ycos5MCTQXiPEO_vEIPzc60ch_sToW_8uJVBnw7A3TwMQbTSW3T_z9TULaXGMkhGTm4LgfXZU5GYiaHZDKbv2FfDrzP-wfyJ5C1 |
CitedBy_id | crossref_primary_10_1039_C6RA25511F crossref_primary_10_1158_1535_7163_MCT_14_0972 crossref_primary_10_4236_jct_2014_514136 crossref_primary_10_3390_cancers13174402 crossref_primary_10_1002_1878_0261_12386 crossref_primary_10_1016_j_biopha_2017_07_075 crossref_primary_10_1507_endocrj_EJ21_0106 crossref_primary_10_1038_s41467_018_04936_9 crossref_primary_10_1093_carcin_bgac089 crossref_primary_10_1016_j_phrs_2023_106915 crossref_primary_10_1146_annurev_genet_121415_121658 crossref_primary_10_1016_j_bcp_2021_114760 crossref_primary_10_1186_s12885_016_2063_1 crossref_primary_10_1158_0008_5472_CAN_17_1671 crossref_primary_10_1111_febs_13285 crossref_primary_10_1002_ajim_23062 crossref_primary_10_3389_fimmu_2016_00128 crossref_primary_10_1038_srep26524 crossref_primary_10_3389_fphar_2021_806570 crossref_primary_10_1002_1878_0261_12034 crossref_primary_10_3892_ol_2021_12892 crossref_primary_10_1111_jcmm_13786 crossref_primary_10_2174_1574892818666230803100554 crossref_primary_10_3390_cancers13010007 crossref_primary_10_4049_jimmunol_1403254 crossref_primary_10_1111_his_13154 crossref_primary_10_3390_nu8050275 crossref_primary_10_1016_j_bioorg_2023_106741 crossref_primary_10_1002_cbin_11399 crossref_primary_10_1074_jbc_M115_691170 crossref_primary_10_1002_jcp_25310 crossref_primary_10_1002_mc_23623 crossref_primary_10_1002_mc_22778 crossref_primary_10_1016_j_prp_2023_154947 crossref_primary_10_3390_biomedicines12092102 crossref_primary_10_1016_j_phrs_2017_12_034 |
Cites_doi | 10.1016/j.ejca.2005.05.009 10.1593/neo.101156 10.1002/ijc.24553 10.1158/1541-7786.MCR-09-0417 10.1158/1541-7786.MCR-09-0313 10.1158/1078-0432.CCR-08-0618 10.1158/1541-7786.MCR-07-0245 10.1111/j.2517-6161.1972.tb00899.x 10.1038/bjc.2012.379 10.1038/nature11003 10.1517/14728222.8.5.409 10.1016/j.ejim.2011.04.002 10.4161/cbt.12.2.15732 10.1177/1947601910375273 10.1074/jbc.M104986200 10.1002/jcb.22558 10.1038/sj.onc.1204086 10.1158/1078-0432.CCR-04-1940 10.1593/neo.06409 10.1039/c3cc46931j 10.1126/science.278.5344.1803 10.1016/j.molonc.2011.03.004 10.1021/mp700113r 10.1200/JCO.2006.09.7634 10.1080/01621459.1958.10501452 10.1101/gad.1421006 10.1007/s00280-011-1655-3 10.1016/j.mehy.2013.09.022 10.2174/138945009789753200 10.5858/2007-131-1350-EOAALS 10.1056/NEJMra050152 10.1007/s40259-013-0058-x 10.1038/sj.cr.7310027 10.1016/j.canlet.2008.03.009 10.1172/JCI0215617 10.1073/pnas.1121606109 |
ContentType | Journal Article |
Copyright | 2014 American Association for Cancer Research. |
Copyright_xml | – notice: 2014 American Association for Cancer Research. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1158/1078-0432.CCR-14-1233 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 5132 |
ExternalDocumentID | 25124686 10_1158_1078_0432_CCR_14_1233 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV CGR CUY CVF ECM EIF NPM RHF 7X8 |
ID | FETCH-LOGICAL-c356t-c28d814fb9a2e24a2d755c304a228d0655e7bab4a94b5563f46752f4c9f078e23 |
ISSN | 1078-0432 1557-3265 |
IngestDate | Fri Jul 11 00:16:23 EDT 2025 Wed Feb 19 02:29:41 EST 2025 Tue Jul 01 03:06:53 EDT 2025 Thu Apr 24 23:08:50 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 19 |
Language | English |
License | 2014 American Association for Cancer Research. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c356t-c28d814fb9a2e24a2d755c304a228d0655e7bab4a94b5563f46752f4c9f078e23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/20/19/5124.full.pdf |
PMID | 25124686 |
PQID | 1586096055 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1586096055 pubmed_primary_25124686 crossref_citationtrail_10_1158_1078_0432_CCR_14_1233 crossref_primary_10_1158_1078_0432_CCR_14_1233 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-10-01 2014-Oct-01 20141001 |
PublicationDateYYYYMMDD | 2014-10-01 |
PublicationDate_xml | – month: 10 year: 2014 text: 2014-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2014 |
References | Ogata (2022061107010404800_bib12) 2006; 8 Gordon (2022061107010404800_bib20) 2002; 62 Pasello (2022061107010404800_bib28) 2009; 10 Li (2022061107010404800_bib34) 2013; 81 Rocks (2022061107010404800_bib37) 2012; 107 Groner (2022061107010404800_bib1) 2014; 382 Cox (2022061107010404800_bib18) 1972; 34 Groner (2022061107010404800_bib40) 2014; 28 Borghouts (2022061107010404800_bib5) 2012; 1 Zhang (2022061107010404800_bib33) 2012; 109 Saydmohammed (2022061107010404800_bib24) 2010; 110 Bromberg (2022061107010404800_bib4) 2002; 109 Groner (2022061107010404800_bib2) 2012; 1 Kaplan (2022061107010404800_bib21) 1958; 53 Garland (2022061107010404800_bib32) 2007; 25 Turkson (2022061107010404800_bib6) 2004; 8 Jakobsen (2022061107010404800_bib27) 2011; 68 Kluge (2022061107010404800_bib14) 2011; 5 Borghouts (2022061107010404800_bib17) 2010; 8 Sharrocks (2022061107010404800_bib7) 2006; 20 Chung (2022061107010404800_bib9) 1997; 278 Robinson (2022061107010404800_bib26) 2005; 353 Anand (2022061107010404800_bib36) 2007; 4 Kluge (2022061107010404800_bib11) 2009; 125 Dabir (2022061107010404800_bib10) 2009; 7 Shuai (2022061107010404800_bib8) 2006; 16 Brantley (2022061107010404800_bib13) 2008; 14 Liu (2022061107010404800_bib35) 2011; 22 Turkson (2022061107010404800_bib3) 2000; 19 Dabir (2022061107010404800_bib15) 2011; 12 Achcar Rde (2022061107010404800_bib25) 2007; 131 Ou (2022061107010404800_bib30) 2011; 13 Li (2022061107010404800_bib39) 2014; 50 Barretina (2022061107010404800_bib19) 2012; 483 Govindan (2022061107010404800_bib31) 2005; 11 Menges (2022061107010404800_bib29) 2010; 1 Sharma (2022061107010404800_bib22) 2005; 41 Unkila (2022061107010404800_bib16) 2001; 276 Kunnumakkara (2022061107010404800_bib23) 2008; 269 Borghouts (2022061107010404800_bib38) 2008; 6 |
References_xml | – volume: 41 start-page: 1955 year: 2005 ident: 2022061107010404800_bib22 article-title: Curcumin: the story so far publication-title: Eur J Cancer doi: 10.1016/j.ejca.2005.05.009 – volume: 13 start-page: 12 year: 2011 ident: 2022061107010404800_bib30 article-title: Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma publication-title: Neoplasia doi: 10.1593/neo.101156 – volume: 125 start-page: 1728 year: 2009 ident: 2022061107010404800_bib11 article-title: Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer publication-title: Int J Cancer doi: 10.1002/ijc.24553 – volume: 1 start-page: 44 year: 2012 ident: 2022061107010404800_bib5 article-title: A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells publication-title: JAKSTAT – volume: 8 start-page: 539 year: 2010 ident: 2022061107010404800_bib17 article-title: The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-09-0417 – volume: 7 start-page: 1854 year: 2009 ident: 2022061107010404800_bib10 article-title: The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-09-0313 – volume: 14 start-page: 4694 year: 2008 ident: 2022061107010404800_bib13 article-title: Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0618 – volume: 6 start-page: 267 year: 2008 ident: 2022061107010404800_bib38 article-title: Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-07-0245 – volume: 34 start-page: 187 year: 1972 ident: 2022061107010404800_bib18 article-title: Regression Models and Life-Tables publication-title: J R Stat Soc Ser B-Stat Methodol doi: 10.1111/j.2517-6161.1972.tb00899.x – volume: 107 start-page: 1083 year: 2012 ident: 2022061107010404800_bib37 article-title: Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer publication-title: Br J Cancer doi: 10.1038/bjc.2012.379 – volume: 382 start-page: 551 year: 2014 ident: 2022061107010404800_bib1 article-title: Molecular and cellular endocrinology: special issue on cytokine signaling publication-title: Mol Cell Endocrinol – volume: 483 start-page: 603 year: 2012 ident: 2022061107010404800_bib19 article-title: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity publication-title: Nature doi: 10.1038/nature11003 – volume: 8 start-page: 409 year: 2004 ident: 2022061107010404800_bib6 article-title: STAT proteins as novel targets for cancer drug discovery publication-title: Expert Opin Ther Targets doi: 10.1517/14728222.8.5.409 – volume: 22 start-page: e31 year: 2011 ident: 2022061107010404800_bib35 article-title: The expression of protein inhibitor of activated signal transducers and activators of transcription 3 in the evolutionary process of gastric cancer publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2011.04.002 – volume: 12 start-page: 139 year: 2011 ident: 2022061107010404800_bib15 article-title: Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors publication-title: Cancer Biol Ther doi: 10.4161/cbt.12.2.15732 – volume: 62 start-page: 4963 year: 2002 ident: 2022061107010404800_bib20 article-title: Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma publication-title: Cancer Res – volume: 1 start-page: 493 year: 2010 ident: 2022061107010404800_bib29 article-title: A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma publication-title: Genes Cancer doi: 10.1177/1947601910375273 – volume: 1 start-page: 211 year: 2012 ident: 2022061107010404800_bib2 article-title: Determinants of the extent and duration of STAT3 signaling publication-title: JAKSTAT – volume: 276 start-page: 39132 year: 2001 ident: 2022061107010404800_bib16 article-title: Unreliability of the cytochrome c-enhanced green fluorescent fusion protein as a marker of cytochrome c release in cells that overexpress Bcl-2 publication-title: J Biol Chem doi: 10.1074/jbc.M104986200 – volume: 110 start-page: 447 year: 2010 ident: 2022061107010404800_bib24 article-title: Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells publication-title: J Cell Biochem doi: 10.1002/jcb.22558 – volume: 19 start-page: 6613 year: 2000 ident: 2022061107010404800_bib3 article-title: STAT proteins: novel molecular targets for cancer drug discovery publication-title: Oncogene doi: 10.1038/sj.onc.1204086 – volume: 11 start-page: 2300 year: 2005 ident: 2022061107010404800_bib31 article-title: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1940 – volume: 8 start-page: 817 year: 2006 ident: 2022061107010404800_bib12 article-title: Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation publication-title: Neoplasia doi: 10.1593/neo.06409 – volume: 50 start-page: 6458 year: 2014 ident: 2022061107010404800_bib39 article-title: Base-catalyzed bicyclization of dialkyl glutaconates with cinnamoylacetamides: a synthetic strategy for isoquinolinedione derivatives publication-title: Chem Commun doi: 10.1039/c3cc46931j – volume: 278 start-page: 1803 year: 1997 ident: 2022061107010404800_bib9 article-title: Specific inhibition of Stat3 signal transduction by PIAS3 publication-title: Science doi: 10.1126/science.278.5344.1803 – volume: 5 start-page: 256 year: 2011 ident: 2022061107010404800_bib14 article-title: Protein inhibitor of activated STAT3 expression in lung cancer publication-title: Mol Oncol doi: 10.1016/j.molonc.2011.03.004 – volume: 4 start-page: 807 year: 2007 ident: 2022061107010404800_bib36 article-title: Bioavailability of curcumin: problems and promises publication-title: Mol Pharm doi: 10.1021/mp700113r – volume: 25 start-page: 2406 year: 2007 ident: 2022061107010404800_bib32 article-title: Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.7634 – volume: 53 start-page: 457 year: 1958 ident: 2022061107010404800_bib21 article-title: Nonparametric Estimation from Incomplete Observations publication-title: J Am Stat Assoc doi: 10.1080/01621459.1958.10501452 – volume: 20 start-page: 754 year: 2006 ident: 2022061107010404800_bib7 article-title: PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases? publication-title: Genes Dev doi: 10.1101/gad.1421006 – volume: 68 start-page: 1 year: 2011 ident: 2022061107010404800_bib27 article-title: Review on clinical trials of targeted treatments in malignant mesothelioma publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-011-1655-3 – volume: 81 start-page: 1151 year: 2013 ident: 2022061107010404800_bib34 article-title: PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer publication-title: Med Hypotheses doi: 10.1016/j.mehy.2013.09.022 – volume: 10 start-page: 1235 year: 2009 ident: 2022061107010404800_bib28 article-title: Molecular targets in malignant pleural mesothelioma treatment publication-title: Curr Drug Targets doi: 10.2174/138945009789753200 – volume: 131 start-page: 1350 year: 2007 ident: 2022061107010404800_bib25 article-title: Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention publication-title: Arch Pathol Lab Med doi: 10.5858/2007-131-1350-EOAALS – volume: 353 start-page: 1591 year: 2005 ident: 2022061107010404800_bib26 article-title: Advances in malignant mesothelioma publication-title: N Engl J Med doi: 10.1056/NEJMra050152 – volume: 28 start-page: 27 year: 2014 ident: 2022061107010404800_bib40 article-title: Targeting survivin in cancer: novel drug development approaches publication-title: Biodrugs doi: 10.1007/s40259-013-0058-x – volume: 16 start-page: 196 year: 2006 ident: 2022061107010404800_bib8 article-title: Regulation of cytokine signaling pathways by PIAS proteins publication-title: Cell Res doi: 10.1038/sj.cr.7310027 – volume: 269 start-page: 199 year: 2008 ident: 2022061107010404800_bib23 article-title: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.03.009 – volume: 109 start-page: 1139 year: 2002 ident: 2022061107010404800_bib4 article-title: Stat proteins and oncogenesis publication-title: J Clin Invest doi: 10.1172/JCI0215617 – volume: 109 start-page: 9623 year: 2012 ident: 2022061107010404800_bib33 article-title: Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1121606109 |
SSID | ssj0014104 |
Score | 2.3294551 |
Snippet | Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined... Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 5124 |
SubjectTerms | Apoptosis - drug effects Apoptosis - genetics Cell Line, Tumor Cell Proliferation - drug effects Curcumin - pharmacology Gene Expression Humans Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - mortality Mesothelioma - genetics Mesothelioma - metabolism Mesothelioma - mortality Mesothelioma, Malignant Molecular Chaperones - chemistry Molecular Chaperones - genetics Molecular Chaperones - metabolism Molecular Chaperones - pharmacology Peptide Fragments - pharmacology Prognosis Protein Inhibitors of Activated STAT - chemistry Protein Inhibitors of Activated STAT - genetics Protein Inhibitors of Activated STAT - metabolism Protein Inhibitors of Activated STAT - pharmacology RNA Interference RNA, Messenger - genetics RNA, Small Interfering - genetics STAT3 Transcription Factor - genetics STAT3 Transcription Factor - metabolism |
Title | Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25124686 https://www.proquest.com/docview/1586096055 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj5swELbSrVT1UvXd9CVX6i0iTYxN4IiyrXabtoc2K-0NGWNapACrkOyh2h-_M8YGWmXVxwUhLEPE92U8Y2a-IeRtHoRhxoPM07D6eFwo5kWwEnoLzQPfD2SeSaP2-SU4OeMfz8X5aHQ1rC7ZpVP182Bdyf-gCtcAV6yS_Qdku5vCBTgHfOEICMPxrzD-hHVsp_E3H4X624RWk7hYgnP9HTNcJqVusMRqU9SlxN7l0qLhks6LCr3GBr3Odbz2jbRGu0nbKgjU9dZJr06aPZiVS_ubnLiBK6xUyJ7txGoHdXvMxzIt2s5elf4hu2yO1WbftnSP-4KKFcyVxjbHmSw7a2T3s4fp_XaTYs67dDdYY6xhFWDMWNsXwlleNhsyLBrYUXBD-GEDL0Kz14C6wNxn0-Xyq4ePY62cxgD0i9Kgjv4bD36X2zYLuBu6RW4zCDKw_8Xx6ar7BsUhUrU1X_DUdwefiVrS9i6_OjY3RCvGa1nfJ_dsuEHjljsPyEhXD8mdzzah4hG5BApRQyHaU4gWFe0oRIcUokVDewpRpBDtKEQNhWhPIQoUokghailEHYUek7MP79fLE8-24vCUL4Kdp1iYhXOep5FkmnHJsoUQyp_BGYyAGyv0IpUplxFPUXIuh_VXsJyrKIfXppn_hBxVdaWfEboAnzaFuBlmSz5PwcWXTKpZmKl5ngeZGhPu3mOirE49tkvZJCZeFWGCSCSIRAJIQOyaIBJjMu2mXbRCLX-a8MaBlIBJxe9kstL1vklgSoCRvRBj8rRFr7ulQ_v5jSMvyN3-H_CSHO22e_0KHNdd-trw6xoqX5TG |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+PIAS3+expression+in+malignant+mesothelioma+is+associated+with+increased+STAT3+activation+and+poor+patient+survival&rft.jtitle=Clinical+cancer+research&rft.au=Dabir%2C+Snehal&rft.au=Kluge%2C+Amy&rft.au=Kresak%2C+Adam&rft.au=Yang%2C+Michael&rft.date=2014-10-01&rft.eissn=1557-3265&rft.volume=20&rft.issue=19&rft.spage=5124&rft_id=info:doi/10.1158%2F1078-0432.CCR-14-1233&rft_id=info%3Apmid%2F25124686&rft.externalDocID=25124686 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |